LLY ELI LILLY & Co

NYSE lilly.com


$ 864.00 $ 18.36 (2.17 %)    

Friday, 31-Oct-2025 19:47:22 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 862.86
$ 840.10
$ 861.00 x 5
$ 864.85 x 1
$ 834.19 - $ 869.91
$ 622.41 - $ 931.66
5,015,016
na
775.54B
$ 0.57
$ 42.12
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-19-2025 12-31-2024 10-K
5 10-30-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 04-30-2024 03-31-2024 10-Q
8 02-21-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 04-27-2023 03-31-2023 10-Q
12 02-22-2023 12-31-2022 10-K
13 11-01-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 04-29-2022 03-31-2022 10-Q
16 02-23-2022 12-31-2021 10-K
17 10-27-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 04-30-2021 03-31-2021 10-Q
20 02-17-2021 12-31-2020 10-K
21 10-28-2020 09-30-2020 10-Q
22 07-31-2020 06-30-2020 10-Q
23 05-01-2020 03-31-2020 10-Q
24 02-19-2020 12-31-2019 10-K
25 10-25-2019 09-30-2019 10-Q
26 08-02-2019 06-30-2019 10-Q
27 05-02-2019 03-31-2019 10-Q
28 02-19-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 07-25-2018 06-30-2018 10-Q
31 04-27-2018 03-31-2018 10-Q
32 02-20-2018 12-31-2017 10-K
33 10-27-2017 09-30-2017 10-Q
34 07-28-2017 06-30-2017 10-Q
35 05-01-2017 03-31-2017 10-Q
36 02-21-2017 12-31-2016 10-K
37 10-28-2016 09-30-2016 10-Q
38 07-28-2016 06-30-2016 10-Q
39 04-29-2016 03-31-2016 10-Q
40 02-19-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

-Reuters

 eli-lilly-seen-in-pole-position-for-growth-analysts-say

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on stro...

 cantor-fitzgerald-maintains-overweight-on-eli-lilly-raises-price-target-to-985

Cantor Fitzgerald analyst Carter Gould maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $92...

 eli-lilly-extends-lead-in-150b-obesity-drug-race-as-novo-pfizer-clash--heres-how-etfs-stand-to-gain

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the...

 meta-tumbles-10-google-marks-historic-rally-whats-moving-markets-thursday

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...

 nvidias-5-trillion-milestone-turns-these-ai-etfs-into-hot-trades

Nvidia's $5 trillion valuation record is igniting momentum across semiconductor and AI-themed ETFs as investors chase the n...

 eli-lilly-executive-says-europe-revenue-increased-by-over-100-in-constant-currency-reflecting-strong-uptake-of-mounjaro-on-mounjaro-says-we-have-now-launched-in-55-countries-and-all-major-markets

-Reuters Citing Conf. Call

 mounjaro-and-zepbound-power-eli-lillys-54-revenue-jump-in-q3-hikes-2025-forecast

Eli Lilly reported Q3 revenue of $17.6 billion, beating estimates and raising 2025 guidance as Mounjaro and Zepbound sales surged.

Core News & Articles

GPRK: 28% | Geopark shares are trading higher after Parex Resources submitted a proposal to acquire all outstanding shares of t...

 eli-lilly-raises-fy2025-gaap-eps-guidance-from-2085-2210-to-2180-2250-vs-2173-est

Eli Lilly (NYSE:LLY) raises FY2025 GAAP EPS guidance from $20.85-$22.10 to $21.80-$22.50 vs $21.73 analyst estimate..

 eli-lilly-raises-fy2025-adj-eps-guidance-from-2175-2300-to-2300-2370-vs-2218-est-raises-fy2025-sales-guidance-from-60000b-62000b-to-63000b-63500b-vs-61650b-est

Eli Lilly (NYSE:LLY) raises FY2025 Adj EPS guidance from $21.75-$23.00 to $23.00-$23.70 vs $22.18 analyst estimate. Raises FY20...

 eli-lilly-q3-adj-eps-702-beats-570-estimate-sales-17601b-beat-16016b-estimate

Eli Lilly (NYSE:LLY) reported quarterly earnings of $7.02 per share which beat the analyst consensus estimate of $5.70 by 23.27...

 eli-lilly-advances-ai-and-access-supercomputer-with-nvidia-zepbound-via-walmart

Eli Lilly partners with NVIDIA to build a powerful AI supercomputer and teams up with Walmart to expand affordable Zepbound acc...

Core News & Articles

Two Nvidia Shockers

 earnings-outlook-for-eli-lilly
Earnings Outlook For Eli Lilly
10/29/2025 15:02:31

 eli-lilly-plans-to-invest-over-12b-to-upgrade-production-site-in-carolina-puerto-rico

Eli Lilly and Company (NYSE:LLY) announced today a planned investment of more than $1.2 billion to expand and modernize its Lil...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION